Literature DB >> 16052306

The importance of factor Xa regulatory pathways in vascular thromboresistance: focus on protein Z.

Richard C Becker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16052306     DOI： 10.1007/s11239-005-2473-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  16 in total

Review 1.  A cell-based model of hemostasis.

Authors:  M Hoffman; D M Monroe
Journal:  Thromb Haemost       Date:  2001-06       Impact factor: 5.249

2.  A common polymorphism of the protein Z gene is associated with protein Z plasma levels and with risk of cerebral ischemia in the young.

Authors:  C Lichy; S Kropp; T Dong-Si; J Genius; T Dolan; T Hampe; F Stoll; K Reuner; C Grond-Ginsbach; A Grau
Journal:  Stroke       Date:  2003-12-11       Impact factor: 7.914

3.  Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo.

Authors:  J Herbert; F Bono; J Herault; C Avril; F Dol; A Mares; P Schaeffer
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

4.  Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery.

Authors:  B P Damiano; M R D'Andrea; L de Garavilla; W M Cheung; P Andrade-Gordon
Journal:  Thromb Haemost       Date:  1999-05       Impact factor: 5.249

5.  Protein Z influences the prothrombotic phenotype in Factor V Leiden patients.

Authors:  Bettina Kemkes-Matthes; Margareta Nees; Gitta Kühnel; Axel Matzdorff; Karl J Matthes
Journal:  Thromb Res       Date:  2002-05-15       Impact factor: 3.944

6.  Characterization of the protein Z-dependent protease inhibitor.

Authors:  X Han; R Fiehler; G J Broze
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

7.  Factor Xa acts as a PDGF-independent mitogen in human vascular smooth muscle cells.

Authors:  E Bretschneider; M Braun; A Fischer; M Wittpoth; E Glusa; K Schrör
Journal:  Thromb Haemost       Date:  2000-09       Impact factor: 5.249

8.  High frequency of protein Z deficiency in patients with unexplained early fetal loss.

Authors:  Jean-Christophe Gris; Isabelle Quéré; Hervé Dechaud; Eric Mercier; Caroline Pinçon; Médéric Hoffet; Marc Vasse; Pierre Marès
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

9.  Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor.

Authors:  R R Forastiero; M E Martinuzzo; L Lu; G J Broze
Journal:  J Thromb Haemost       Date:  2003-08       Impact factor: 5.824

10.  Low protein Z levels and risk of ischemic stroke: differences by diabetic status and gender.

Authors:  Mary J Heeb; Annlia Paganini-Hill; John H Griffin; Mark Fisher
Journal:  Blood Cells Mol Dis       Date:  2002 Sep-Oct       Impact factor: 3.039
View more
  2 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Participation of protein Z-dependent protease inhibitor and protein Z system in the pathomechanism of thrombotic complications.

Authors:  Małgorzata A Gacka; Rafał Małecki; Rajmund Adamiec
Journal:  Int J Angiol       Date:  2010
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.